Impact of Obesity on the Drug–Drug Interaction Between Dolutegravir and Rifampicin or Any Other Strong Inducers

BACKGROUND: Obesity is increasingly prevalent among people with HIV. Obesity can impact drug pharmacokinetics and consequently the magnitude of drug–drug interactions (DDIs) and, thus, the related recommendations for dose adjustment. Virtual clinical DDI studies were conducted using physiologically...

Descripción completa

Detalles Bibliográficos
Autores principales: Berton, Mattia, Bettonte, Sara, Stader, Felix, Battegay, Manuel, Marzolini, Catia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368306/
https://www.ncbi.nlm.nih.gov/pubmed/37496606
http://dx.doi.org/10.1093/ofid/ofad361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368306/
https://www.ncbi.nlm.nih.gov/pubmed/37496606
http://dx.doi.org/10.1093/ofid/ofad361

Ejemplares similares